JAMP Pharma Corp. Recalls Pregabalin Pain Medication Due to Mislabeling

JAMP Pharma Corp. has announced a recall of one lot of its pregabalin pain medication after it was discovered that some bottles labelled as containing 50-milligram capsules actually contain 150-milligram capsules instead. This mislabeling could potentially lead to patients receiving a much higher dose than prescribed, posing serious health risks, including the possibility of overdose.

Pregabalin, sold under the brand name JAMP-Pregabalin, is a prescription drug used in adults to treat pain caused by nerve damage from conditions such as diabetes, shingles, spinal cord injury, and fibromyalgia. Symptoms of pregabalin overdose can include sudden mood changes, sleepiness, confusion, depression, agitation, restlessness, and seizures. It is important to note that taking too much pregabalin in conjunction with other central nervous system-acting drugs, such as opioids, can lead to heart electrical issues, seizures, and even death.

If you suspect that you are experiencing symptoms of an overdose, it is crucial to seek immediate medical attention. Patients should not abruptly discontinue pregabalin, as this could result in withdrawal symptoms like insomnia, nausea, headache, anxiety, excessive sweating, diarrhea, and convulsions.

Health Canada advises individuals who have been prescribed 50-milligram capsules and find that their bottle contains the higher dose, or are unsure, to return the product to their pharmacy. If returning the capsules immediately is not possible, it is recommended to consult with a pharmacist or doctor for further guidance. The affected product was distributed nationwide.